The Alzheimer's Drug That Just Escaped the Waiting Room
Leqembi just became the first Alzheimer's drug you can take entirely at home, from first dose to last. With nine-month clinic waitlists and infusion-center bottlenecks choking patient access, this FDA approval could reshape who actually gets treated.
Imagine needing a life-altering medication, but the only way to get it is sitting in an infusion chair at a specialized clinic every two weeks. Now imagine the waitlist for that chair is months long. That's been the reality for thousands of Alzheimer's patients trying to access Leqembi.
Until now.
The 30-Second Treatment
On July 13, the FDA approved an at-home starting dose for Leqembi IQLIK, the subcutaneous autoinjector version of Eisai and Biogen's anti-amyloid Alzheimer's drug lecanemab. Patients with early Alzheimer's can now begin treatment from day one at home, using two quick injections that take about 15 seconds each.
That's 30 seconds on your couch versus hours in a clinic. Every single week, instead of showing up to an infusion center every two weeks for an IV drip.
This makes Leqembi the first anti-amyloid Alzheimer's therapy that can be given at home for maintenance dosing, with the at-home starting dose now also approved. No infusion center required.
Why This Matters More Than It Sounds
To understand why this is a big deal, you need to understand the bottleneck that's been strangling Alzheimer's treatment in America.
Leqembi got accelerated FDA approval in January 2023, followed by full traditional approval in July 2023. The drug actually works; it slowed cognitive decline by about 27% over 18 months in its pivotal trial. About 68% of patients on it cleared their amyloid plaques on brain scans. By the standards of Alzheimer's therapeutics, that's a genuine breakthrough.
But having a drug that works and getting it to patients are two very different problems.
The original Leqembi required IV infusions every two weeks at a specialized center. The U.S. has roughly 853 infusion sites offering the drug. Sounds like a lot, right? Not when you consider the math. An estimated 1.4 million patients were initially eligible, and those centers aren't evenly distributed.
Eleven states have five or fewer clinics offering Leqembi. Some patients face 50 to 100 mile drives, round trip, every two weeks. Washington University in St. Louis had 100 patients in its queue with three- to four-month waits.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
One large infusion network with 35 centers reported only about 100 Leqembi patients total. That's roughly three per center. The demand was there. The infrastructure wasn't.
The Infusion Center Problem Is Really a Dozen Problems
The bottleneck wasn't just about chairs. It was a cascading series of obstacles that made getting treated feel like navigating a bureaucratic obstacle course.
First, you need a neurologist or dementia specialist to evaluate you. Those are in short supply, especially outside major metro areas. Then you need amyloid confirmation through a PET scan or spinal fluid test. Then a baseline brain MRI. Then insurance approval. One hospital reported it took three months just to get approval to hire a nurse to help coordinate Leqembi patients. Another center needed a five-year business plan to secure infusion beds.
And even after clearing all those hurdles, the risks, costs, time commitment, and the reality of biweekly clinic visits stretching out indefinitely caused many eligible patients to decline treatment.
The annual list price sits around $26,500. Medicare covers it now, but younger patients or those on certain commercial plans can still face gaps. Travel costs? Not covered.
All of this explains why Leqembi's early sales were modest. Biogen reported $19 million in Q1 2024, nearly triple the prior quarter but still far from blockbuster territory. The drug was growing fast in percentage terms, but from a tiny base.
How Escaping the Clinic Changes the Game
The at-home approval attacks the problem at its root. If patients don't need infusion centers, the infusion center shortage stops mattering as much.
The new regimen is simple: 500 mg per week, delivered as two 250 mg subcutaneous injections via a pre-filled autoinjector. A healthcare provider supervises at least the first two doses. After that, patients or caregivers can handle it at home.
The pharmacokinetic data backing this up is solid. The weekly subcutaneous dose achieved 104% of the drug exposure compared to the IV regimen (90% confidence interval: 99.1% to 109%), which qualifies as bioequivalent. Clinical outcomes, biomarker results, and safety profiles all tracked consistently with the IV version.
Previously, Eisai and Biogen had already gotten the autoinjector approved for maintenance dosing (the ongoing treatment phase) back in August 2025. But patients still had to start with 18 months of IV infusions before switching. That was like telling someone they could work from home, but only after commuting to the office for a year and a half first.
Now, the entire journey can happen at home. Specialty pharmacies will distribute the autoinjectors, with a U.S. launch planned for late August 2026.
The Safety Question Nobody Should Ignore
Convenience is great, but Leqembi isn't a vitamin. These anti-amyloid antibodies carry a real risk called ARIA (amyloid-related imaging abnormalities), which can cause brain swelling or microbleeds. Most cases are mild and resolve on their own. Some are asymptomatic, caught only on routine MRI scans.
But rare cases can be serious: seizures, significant neurological problems, even fatal brain hemorrhages. Leqembi carries a boxed warning about this. The risk is especially elevated in people who carry two copies of the APOE ε4 gene, a known Alzheimer's risk factor.
Here's the critical nuance: ARIA risk doesn't change based on where you get the injection. It's driven by the drug itself and your genetic profile, not the setting. What does change is how quickly someone notices a problem.
In an infusion center, trained staff screen you before every dose. They can spot confusion, headaches, or other warning signs in real time and order an urgent MRI. At home, that responsibility falls on patients and caregivers.
The FDA's approach reflects this reality. Patients still need scheduled MRIs at defined intervals. They still need APOE ε4 testing before starting. They still need to know exactly what symptoms should trigger an emergency call. The monitoring infrastructure doesn't go away; it just gets reorganized.
Less than 1% of patients on the subcutaneous formulation experienced systemic injection reactions. Injection-site reactions (redness, mild swelling) were the most common side effect specific to the autoinjector, and they were generally mild.
What Wall Street Thinks (and Why They're Cautiously Excited)
Biogen's stock dropped about 8–9% on the day of the approval, though it rebounded in subsequent days. Multiple analyst firms raised their price targets. Truist upgraded Biogen to Buy with a $235 target. Wedbush moved to $201. RBC reiterated Outperform at $242.
But the tone from most analysts was "this helps, not transforms." BMO Capital Markets noted the at-home option could boost uptake and differentiate Leqembi from its main competitor. Citi, however, was explicit: they don't expect an immediate commercial inflection. The structural barriers (slow diagnosis, specialist shortages, MRI monitoring, insurance logistics) haven't disappeared. They've just gotten one layer thinner.
The more optimistic models see Biogen reaching roughly $10.7 billion in total revenue by 2029, with bulls pushing that to $12 billion by 2030. Leqembi's at-home evolution makes those higher numbers more plausible, but the thesis still depends on how fast the healthcare system can adapt.
The Competitive Angle: Leqembi vs. Kisunla
Leqembi isn't alone in this market. Eli Lilly's Kisunla (donanemab) got full FDA approval in July 2024 and has its own selling points. Kisunla requires infusions only once a month, half as often as IV Leqembi. And its label allows doctors to stop treatment once amyloid plaques are sufficiently cleared, potentially reducing long-term costs.
But Kisunla has two significant disadvantages. First, its ARIA rates are considerably higher: 24% for brain swelling versus about 12.6% for Leqembi. Brain microbleeds hit 31.4% with Kisunla versus lower rates for Leqembi. In a disease where patients are already anxious about brain-related side effects, that gap matters.
Second, and now more critically, Kisunla has no subcutaneous formulation. It's IV only. As of this approval, Leqembi can be given entirely at home while Kisunla patients still need to show up at infusion centers every month.
Biogen has been blunt about this. Executives have said that Kisunla's dosing convenience advantage "is going to go away once we have a subcutaneous formulation." That moment has arrived.
Analysts at RBC project Leqembi could capture roughly 60% of the U.S. market by 2030, versus about 25% for Kisunla. GlobalData estimates put 2030 global sales at $3.5 billion for Leqembi and $2.0 billion for Kisunla. As of early 2026, the two drugs are roughly neck and neck in market share. The at-home approval could be what tips the scale.
The Bigger Picture
This isn't just about one drug getting a more convenient delivery method. It's a test case for whether breakthrough therapies can actually reach the patients who need them.
Alzheimer's affects millions. The eligible population for anti-amyloid drugs will only grow as diagnostics improve and earlier-stage patients become candidates. (Leqembi is already being studied in the AHEAD 3-45 trial for people with elevated amyloid but no symptoms yet.)
If at-home treatment can crack open the access bottleneck, the implications extend beyond Alzheimer's. Every antibody therapy that currently chains patients to infusion centers is watching this experiment closely.
For now, the 30-second injection at the kitchen table beats the long wait for a clinic chair. And sometimes, that's how revolutions start: not with a bang, but with a very small needle.
Funding & Financings5 min read
Uncle Sam Just Bet $160M That Gene Therapy Can Work Like Software
ARPA-H just dropped $160 million on seven teams racing to make gene therapy work like a software platform: swap one piece of code, treat a whole new disease. If the aggressive timelines and novel regulatory models pan out, it could reshape how we think about curing the rarest genetic conditions.
